Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 4281 - 4288 of 11613 results
CCPA QOTD: What are the employee/applicant and “business to business” exemptions?
December 19, 2019| Blog| Viewpoint
Consumer Product Regulatory Priorities in 2019: An Ever-Shifting Landscape for FDA
December 19, 2019| Blog| Viewpoint
CCPA QOTD: What are the penalties for non-compliance with the CCPA?
December 18, 2019| Blog| Viewpoint
District Court denies motion to dismiss despite Federal Circuit’s finding of patent invalidity in appeal of parallel ITC investigation
December 18, 2019| Blog| Viewpoint
Means-Plus-Function Structure – Can It Be Incorporated by Reference?
December 18, 2019| Blog| Viewpoint
When is an Interim International Arbitral Award “Final” Enough for Judicial Enforcement?
December 18, 2019| Blog| Viewpoint
HHS Proposes Sweeping Changes to AKS and Stark Law, Part 6: Proposed Changes to the AKS Related to Beneficiary Inducement
December 18, 2019| Blog| Viewpoint
Board Oversight Of ‘Soft Assets’ Are An Opportunity For Increasing Returns
December 17, 2019| News
News & Press Releases
Mintz Announces New Members
December 20, 2024
Mintz announces the election of eight attorneys to Members, effective January 1, 2025. The newly promoted Members join the ranks of the firm’s growing membership, including six new lateral Members who joined the firm in 2024.
Mintz represented the US Department of Energy (DoE) Loan Programs Office (LPO) in the closing of a $1.45 billion loan guarantee to Hanwha Q Cells Georgia, Inc. (QCells), a leading North American crystalline silicon solar manufacturer.
Dealmaking Dormant No More
December 17, 2024
International Chair of Life Sciences Cheryl Reicin recently participated in a Q&A with Pharmaceutical Executive in which she discusses the ongoing effects of the pandemic on dealmaking trends in the pharmaceutical industry. Cheryl specifically mentions how M&A activity began to rise again in 2024 after slowing in 2023, and that she expects acquisitions to continue picking up in 2025.